Provided are VLA-4 antagonists, with an exemplary structure (iia) as depicted. The compounds are conjugates of a bio-compatible polymer moiety and a branched-arm hub molecule and can comprise multiple polyethylene glycol moieties. The conjugate compounds can be alpha4beta1 or alpha4beta7 inhibitors and can be used to treat inflammation and autoimmune diseases.